澳门大阳城122.ccapp官方下载

目录产品 » 重组蛋白 » SARS-CoV-2 Nucleocapsid protein
Manual
SDS
COAs

SARS-CoV-2 Nucleocapsid protein

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.
￥3800
Z03488

产品简介
Species SARS-CoV-2
Protein Construction
N protein (Ser2-Ala419)
Accession # P0DTC9
Purity > 90% as analyzed by SDS-PAGE
Biological Activity SARS-CoV-2 Nucleocapsid protein can bind with SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric(Cat. No. A02039) in functional ELISA assay.
Expression System E. coli
Theoretical Molecular Weight 46 kDa
Formulation Supplied as a solution in PBS pH 7.4 containing 10% glycerol.
Concentration Please refer to the COA for the specific lot.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles.
返回

图例
SARS-CoV-2 Nucleocapsid Protein

»

SARS-CoV-2 Nucleocapsid Protein

»

SARS-CoV-2 Nucleocapsid Protein

Immobilized SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (Cat. No. A02039) at 2 μg/mL can bind SARS-CoV-2 Nucleocapsid protein (Cat. No. Z03488) with a serial dilution.
SARS-CoV-2 Nucleocapsid Antibody (HC2003) conjugated Biotin and Streptavidin-HRP (M00091), are used as a secondary antibody (1 μg/mL, 0.2 μg/mL). »

SARS-CoV-2 Nucleocapsid Protein

Lane 1: 1μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 2: 3μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 3: 5μg of SARS-CoV-2 Nucleocapsid protein, reducing(R)
Lane 4: 5μg of SARS-CoV-2 Nucleocapsid protein, non-reducing(NR)
> 90% as analyzed by SDS-PAGE »

<
>

技术背景
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.
Synonyms Coronavirus NP; coronavirus Nucleocapsid; coronavirus Nucleoprotein; Novel coronavirus Nucleoprotein; 2019-nCoV N protein
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Razieh Salahandish, et al. A compact, low-cost, and binary sensing (BiSense) platform for noise-free and self-validated impedimetric detection of COVID-19 infected patients. Biosens Bioelectron. (2022-06)
Nicolás A Muena, et al. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. EBioMedicine. (2022-03)
Gang Zeng, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. (2021-12)
Jayamohan H, et al. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. Analytical and Bioanalytical Chemistry. (2021-01)
Jennifer M Dan, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. (2021-01)
Andrei Komarov, et al. Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing. Diagnostics (Basel). (2021-01)
Ripperger TJ, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. (2020-11)
Rydyznski Moderbacher C, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. (2020-11)
Adriana Savastano, et al. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. biorxiv. (2020-06)